Took a look at this, MATH+1 appears to be less effective in mechanical ventilator dependent patients, with a survival rate of 33% in one study (1.). This contrasts to our trials where the eligibility criteria is patients "requiring mechanical ventilatory support".
The crucial factor with the MATH+1 protocol and its effectiveness is the timing of its application - needs to applied early to demonstrate higher success according to sources online. I think there's yet to be any reports with sufficient data demonstrating how effective this protocol has been (and under what criteria/circumstances), we shall see.
Remestemcel-L has shown positive results in the worst scenarios (and the interim readout hopefully confirms this), so I'd say we're in the green.
Took a look at this, MATH+1 appears to be less effective in...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.15 |
Change
0.025(2.22%) |
Mkt cap ! $1.313B | |||
| Open | High | Low | Value | Volume |
| $1.16 | $1.19 | $1.13 | $8.289M | 7.186M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 22569 | $1.14 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.15 | 105374 | 2 |
View Market Depth
| Last trade - 16.10pm 22/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.15 |
Change
0.025 ( 2.46 %) |
||||
| Open | High | Low | Volume | ||
| $1.16 | $1.19 | $1.13 | 1229288 | ||
| Last updated 15.59pm 22/05/2024 ? | |||||
| MSB (ASX) Chart |